MTOR and colorectal carcinoma: To evaluate whether oncolytic virus–mediated p53 activation suppresses the expression of mTOR in BRAF-mutant CRC cells, BRAF-mutant HT29 cells were treated with OBP-301 and p53-expressing Ad-p53 or non-expressing control DL312 for 72 h.